HOOK (HOOKIPA Pharma) Days Payable : 0.00 (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is HOOKIPA Pharma Days Payable?

HOOKIPA Pharma's average Accounts Payable for the three months ended in Dec. 2024 was $8.82 Mil. HOOKIPA Pharma's Cost of Goods Sold for the three months ended in Dec. 2024 was $0.00 Mil.

The historical rank and industry rank for HOOKIPA Pharma's Days Payable or its related term are showing as below:

HOOK's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 122.35
* Ranked among companies with meaningful Days Payable only.

HOOKIPA Pharma's Days Payable stayed the same from Dec. 2023 (0.00) to Dec. 2024 (0.00). stayed the same

HOOKIPA Pharma Days Payable Historical Data

The historical data trend for HOOKIPA Pharma's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HOOKIPA Pharma Days Payable Chart

HOOKIPA Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Days Payable

Get a 7-Day Free Trial

HOOKIPA Pharma Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Days Payable	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of HOOKIPA Pharma's Days Payable

For the Biotechnology subindustry, HOOKIPA Pharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HOOKIPA Pharma's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HOOKIPA Pharma's Days Payable distribution charts can be found below:

* The bar in red indicates where HOOKIPA Pharma's Days Payable falls into.

HOOKIPA Pharma Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

HOOKIPA Pharma's Days Payable for the fiscal year that ended in Dec. 2024 is calculated as

	Days Payable (A: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2023 )	+	Accounts Payable (A: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2024 )	*	Days in Period
=	( (12.498	+	8.687)	/	2 )	/	0	*	365
=	10.5925					/	0	*	365
=	N/A

HOOKIPA Pharma's Days Payable for the quarter that ended in Dec. 2024 is calculated as:

	Days Payable (Q: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2024 )	+	Accounts Payable (Q: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2024 )	*	Days in Period
=	( (8.955	+	8.687)	/	2 )	/	0	*	365 / 4
=	8.821					/	0	*	365 / 4
=	N/A

HOOKIPA Pharma Days Payable Related Terms

Thank you for viewing the detailed overview of HOOKIPA Pharma's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

HOOKIPA Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HOOKIPA Pharma Inc (NAS:HOOK) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

350 Fifth Avenue, 72nd Floor, Suite 7240, New York, NY, USA, 10118

Website

https://www.hookipapharma.com

HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.

Executives

Reinhard Kandera	director, officer: Chief Financial Officer	C/O HOOKIPA PHARMA INC., 430 EAST 29TH ST., 14TH FLOOR, NEW YORK NY 10016
Jorn Aldag	director, officer: Chief Executive Officer	C/O UNUM THERAPEUTICS INC., 200 CAMBRIDGE PARK DRIVE SUITE 3100, CAMBRIDGE MA 02210
Mary Theresa Coelho	director	52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017
Katia Schlienger	officer: Chief Medical Officer	350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK NY 10118
Malte Peters	director	TANGO THERAPEUTICS, INC., 100 BINNEY STREET, UNIT 700, CAMBRIDGE MA 02142
Timothy P. Reilly	director	C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK NY 10018
Gilead Sciences Inc	10 percent owner	333 LAKESIDE DR, FOSTER CITY CA 94404
Igor Matushansky	officer: Chief Medical Officer	C/O HOOKIPA PHARMA INC., 430 EAST 29TH STREET, NEW YORK NY 10016
Sofinnova Capital Vi Fcpr	10 percent owner	C/O SOFINNOVA PARTNERS, 17 RUE DE SURENE, PARIS XX 75008
Christine D. Baker	officer: Chief Business Officer	C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK NY 10118
Jean-charles Soria	director	C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE SUITE 7240, NEW YORK NY 10118
Anders Lilja	officer: Sr. VP, Technical Development	C/O HOOKIPA PHARMA INC., 430 EAST 29TH ST., 14TH FLOOR, NEW YORK NY 10016
Klaus Orlinger	officer: Sr. VP, Research	C/O HOOKIPA PHARMA INC., 430 EAST 29TH STREET, 14TH FLOOR, NEW YORK NY 10016
Roman Necina	officer: Chief Technology Officer	C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK NY 10118
Forbion Capital Fund Ii Cooperatief U.a.	10 percent owner	C/O HOOKIPA PHARMA INC., 430 EAST 29TH STREET, 14TH FLOOR, NEW YORK NY 10016